Materials and Methods

Surgical Procedure
Our experimental protocol was approved by the Institutional Animal Care and Use Committee of Dartmouth College and was conducted according to the accepted standards of the National Institutes of Health. Male Sprague-Dawley rats weighing between 300 and 360 g were used for the experiments. Anesthesia was induced by administration of 4% halothane in oxygen and the animals were allowed to breathe spontaneously. Anesthesia was maintained with 1% to 1.5% halothane inhalation. The right femoral artery and vein were cannulated for blood sampling, measurement of arterial blood pressure and administration of fluids and drugs. A rectal temperature probe was connected to a temperature controller coupled to a heating blanket; core temperature was maintained within the normal physiological range (37.5˚ Ϯ 0.60˚C). To be certain that cephalic temperature correlated closely with core temperature, 20 rats underwent simultaneous monitoring of core and temporalis muscle temperatures. Temporalis muscle temperatures were determined using an optical fiber thermometer probe. There was no significant difference in temperature between sites during infusion of vehicle or MgSO 4 , induction of ischemia, or at the time of reperfusion. Arterial blood pressure was monitored and blood samples were evaluated for pH, PaCO 2 , PaO 2 , and serum glucose before ischemia was induced and for 45 minutes thereafter. Blood samples for measurement of plasma magnesium concentration were obtained just before injection of the MgSO 4 , 15 minutes and 60 minutes after establishing middle cerebral artery (MCA) occlusion and after 15 minutes of reperfusion. The volume of blood withdrawn was replaced by an equal volume of intravenous normal saline.
Using the operating microscope, we made a midline ventral neck incision and isolated the right common carotid artery (CCA), external carotid artery (ECA), and internal carotid artery (ICA). The occipital and superior thyroid branches of the ECA were coagulated and divided and the ECA was ligated with two No. 6-0 silk sutures placed distal to the latter branch. The pterygopalatine artery was ligated close to its origin at the ICA. The CCA and ICA were temporarily occluded using microvascular clips, and the ligated ECA was cannulated with a 22-gauge catheter, whose tip was advanced close to the carotid bifurcation and secured there. Following removal of the clips, MgSO 4 or vehicle was infused via the catheter and the catheter was removed. A monofilament nylon suture, 250 m in diameter with a rounded and polished tip, was advanced via the ECA 19 to 21 mm into the ICA from the CCA bifurcation to occlude the MCA. 25, 58 The length of suture varied according to the rat's body weight. The incision was closed and the rat was allowed to awaken.
Following 90 or 120 minutes of ischemia, the rats were reanesthetized and reperfusion was achieved by retracting the occluding suture until its tip reached the ECA stump. Blood flow from the CCA to the ICA was visually confirmed by means of the operating microscope. After establishing the reperfusion, the rats were returned to their cages for 24 hours, at which time they were evaluated neurologically in the manner described by Bederson, et al., 5 and then killed.
To confirm the correct positioning of the occluding suture, 2 ml/kg of 2% Evans blue dye was injected intravenously and allowed to circulate for 30 minutes. This dye stains the vessel along the path of the suture and shows the position of the suture in the MCA. Sham-operated animals were subjected to a similar operative procedure; however, the occluding filament was advanced and then immediately withdrawn.
Experimental Groups
Sixty-five rats were subjected to 1.5 hours (42 animals) or 2 hours (23 animals) of reversible MCA occlusion. Before surgery, the animals were randomly assigned to receive equal volumes (0.2 ml) of MgSO 4 , vehicle (5% dextrose in water), or normal saline prior to occlusion. The results in animals given vehicle were not significantly different from those in animals infused with saline and the two groups were later pooled into a single control group. Thus, three treatment groups were used. Twenty-four rats received a 5% solution of MgSO 4 (to a dose of 30 mg/kg), 18 animals were given a 15% solution of MgSO 4 (90-mg/kg dose), and 23 control animals were injected with the same volume of vehicle or saline. Because the rapid intravenous injection of magnesium salts may induce a cardiodepressant effect and hypotension, MgSO 4 or vehicle was infused over a 10-minute period at a rate of 0.02 ml/minute. The rate of intraarterial infusion of the drug was chosen on the basis of pilot experiments in our laboratory that demonstrated no hypotensive effects. The doses of MgSO 4 were chosen to correspond to those used in clinical practice, in which loading doses of 30 and 90 mg/kg have been reported to be effective in the treatment of preeclampsia. 6 Measurements of infarct size, histopathology, and neurological outcome were performed by an individual blind to the animal's group. Animals with subarachnoid hemorrhage due to vessel injury by the suture and/or animals that died within 24 hours were discarded from this analysis. Fifty-seven rats developed full infarctions involving both the cortex and the striatum; the remaining eight rats, six of which were in the 90-mg/kg treatment group, had only striatal infarction or no infarction on staining, despite a correctly positioned intraluminal suture. Only animals with full infarction (57 animals) were used for data analysis in this study, although this may have underestimated the efficacy of MgSO 4 as a cytoprotective agent. Five rats underwent sham operations and were processed for histological examination.
Measurement of Infarction
Animals were killed while under halothane anesthesia by intracardiac injection of hyperosmolar KCl solution. The brains were removed rapidly and sectioned in a rodent brain matrix into five, 2-mm-thick coronal sections, starting at 3 mm from the frontal pole. Sampling encompassed the entire span of the lesion, with the exception of a small portion extending into the frontal pole. The sections were incubated for 30 minutes at 37˚C in a 2% solution of 2Ј,3Ј,5Ј-triphenyl-2H-tetrazolium chloride (TTC) to stain for mitochondrial dehydrogenase activity. 5 The unstained area in each section was traced and quantified using a video digitizer and a computerized image analysis system (Image 1.55; National Institutes of Health, Rockville, MD) as were the total right and left hemispheric areas. The total infarction volume was then calculated by multiplying the area of infarct in each slice by the slice thickness. The extent of infarction was expressed as a percentage of the whole measured brain volume. Cortex and basal ganglia were outlined separately. Brain edema that contributed to the infarction volume was expressed as a percentage of the difference in both hemispheric volumes to the whole measured brain volume. 51 After the initial TTC measurements were obtained, the slices were stored in a 10% formalin solution until histological evaluation was performed.
Histopathological Examination
Thirty brains were processed for evaluation of the effects of treatment on ischemic cell damage after reversible MCA (five in the sham-operated group, 15 in the 1.5-hour MCA occlusion group, and 10 in the 2-hour MCA occlusion group). Histological sections stained with hematoxylin and eosin and with acid fuscian were obtained from the frontal surface of the 2-mm-thick paraffin block corresponding to section No. 2 of the TTC examination (5-7 mm from the frontal pole). This region was consistently centered in the infarcted tissue. The level of the anterior commissure (stereotactic level A 7470 m) was used for additional histological examination. 26 Direct counting of histologically intact neurons was performed in 40 nonoverlapping fields in the infarct border zone (dorsolateral neocortex) and in the homotopic area of the contralateral, nonischemic hemisphere. We applied our previously described light microscopic criteria for evaluation of acute ischemic neuronal damage. 28 Morphological features, such as pyknosis/eosinophilia and loss of hematoxylin affinity, were interpreted as indicators of irreversible cell damage.
14 Results from cell counting were presented as the percentage of histologically intact neurons in the ischemic hemisphere compared to intact neurons in homotopic regions of the nonischemic hemisphere. Corresponding data from counts in the sham-operated rats were given as a right-to-left hemisphere ratio in percent.
Statistical Analysis
All data are presented as the mean Ϯ standard deviation. For a comparison among experimental groups, an analysis of variance and Student's t-test were used. Probability values less than 0.05 were considered statistically significant. The Mann-Whitney U-test was used for analysis of nonparametric data such as neurological outcome.
Results
The physiological variables did not differ significantly between vehicle and treatment groups (Table 1) . Moderate hyperglycemia was noted in all groups. A trend toward increased glucose levels after MCA occlusion was observed, although this did not reach statistical significance. Intracarotid MgSO 4 infusion did not induce significant hemodynamic effects (mean arterial blood pressure (MABP) reduction Ͻ 10% of baseline), although a transient reduction in heart rate was noted at the start of MgSO 4 infusion. The 30-mg/kg MgSO 4 dose produced a short-lasting (Ͻ 1 hour) elevation in plasma Mg ++ levels from 0.76 Ϯ 0.11 mmol/L to 1.08 Ϯ 0.13 mmol/L. In the 90-mg/kg MgSO 4 group, the plasma Mg ++ concentration increased from 0.74 Ϯ 0.09 mmol/L to 1.49 Ϯ 0.18 mmol/L and the hypermagnesemia lasted for more than 1 hour (Fig. 1) .
Fifty-seven rats developed full infarctions involving both the cortex and the striatum. All animals subjected to 2 hours of MCA occlusion and 11 of 12 animals in both the vehicle and 30-mg/kg MgSO 4 groups subjected to 1.5 hours of MCA occlusion developed full infarctions. However, only 12 of 18 rats with 90 mg/kg MgSO 4 and 1.5 hours of occlusion developed full infarctions. This was significantly different from the vehicle and the 30-mg/kg MgSO 4 groups (p Ͻ 0.05). The effect of MgSO 4 on infarct size, as well on brain edema, is summarized in Table 2 . Infarct volume was significantly decreased in treatment groups when compared to controls. Attenuation of edema was pronounced in the 1.5-hour MCA occlusion-90-mg/kg MgSO 4 rats. This group also displayed a significantly lower neurological deficit score (Table 3) .
The cerebroprotective effect of MgSO 4 in the 2-hour ischemia group resulted from sparing the cortex (Fig. 2  upper) , whereas the rats subjected to 1.5-hour MCA occlusion demonstrated protection of both cortex and basal ganglia (Fig. 2 lower) . The mean infarct size was not significantly different between the 1.5-and 2-hour control
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Magnesium sulfate in reversible cerebral ischemia 119 The reduction in the total infarct volume in the 2-hour occlusion group was evident in the caudal sections, whereas in the 1.5-hour ischemia group, the protection was apparent both as attenuation of the infarct area in individual slices as well as in its rostrocaudal extent (Fig. 3) .
Analysis of variance confirmed a statistically significant effect of MgSO 4 treatment on infarct volume across all groups (F = 22.95, p Ͻ 0.0001). However, the study was not powerful enough to determine the relationship between length of ischemia and infarct volume (F = 2.08, power 0.29). There was no interaction between length of ischemia and MgSO 4 dose.
The percentage of histologically intact neurons in the infarct border was greater in MgSO 4 -treated rats. Surprisingly, the difference was statistically significant only for the 30-mg/kg group (Fig. 4) . We believe that this is due to a less sharply demarcated border zone in the 90 mg/kgtreated rats because of a larger transitional area adjacent to a smaller infarct core in this group.
Discussion
The data presented here demonstrate that significant neuroprotection, measured as a reduction in infarct size, has been achieved with preischemic, intraarterial administration of MgSO 4 in a rat model of reversible focal ischemia. Animals that were subjected to 1.5 hours of MCA occlusion after receiving 90 mg/kg MgSO 4 had the smallest infarct volume and demonstrated significantly decreased cerebral edema formation compared to other groups. This supports the concept that cerebral edema in focal ischemia is related to infarct size, as recently suggested by Slivka, et al. 50 Previous reports have shown that magnesium improves blood flow to ischemic cortex and attenuates infarct size in focal cerebral ischemia in rats. 9, 21 However, those studies evaluated permanent MCA occlusion models and are not as applicable as the present study to the clinical setting of cerebrovascular surgery. In addition, the present study used a unique treatment regimen of preischemic, intraarterial administration of a single-bolus, clinically applicable dose of drug administered to the same side as the ischemia. We think this model is relevant to the clinical situation that may occur during cerebrovascular procedures when one wishes to deliver a potentially cytoprotective agent to a vascular territory that is to be rendered transiently ischemic.
Our data demonstrate that the cytoprotective effects of MgSO 4 are dose dependent for the two doses studied. However, even at the 90-mg/kg dose the plasma magnesium concentration was considerably lower than that found after systemic administration of magnesium in most previous reports on the effects of magnesium salts. 7, 9, 21, 36, 49, 52, 57 We do not know the concentration of magnesium in the brain following intraarterial administration. However, the neuroprotection we were able to demonstrate was more prominent than that specified in previous studies of the cytoprotective effects of magnesium and we suspect that this efficacy may be due to the intraarterial method of administration used in our experimental protocol.
There are several possible explanations for the capability of MgSO 4 to ameliorate ischemic injury when given intraarterially before inducing ischemia. When administered intravenously in high concentrations, magnesium is transported into the cerebrospinal fluid. 39, 53 It is well documented that elevated parenchymal concentrations of magnesium exert a cytoprotective effect during ischemia.
In vitro experiments using superfused rat hippocampal slices 23, 45 and isolated rabbit retina, 3 in which minimal diffusional barriers exist and high magnesium concentrations can be achieved, have unequivocally demonstrated the protective action of magnesium against anoxic neuronal damage. When administered directly to the hippocampus, magnesium salts have also been effective in limiting ischemic damage to CA1 pyramidal cells, even when given up to 24 hours after the ischemic episode. 54 In vivo studies have shown the benefits of systemically administered magnesium in experimental models of permanent focal cerebral ischemia, 9, 21 spinal cord ischemia, 55 traumatic brain injury, 30 topically induced quinolinate hippocampal neurodegeneration, 57 perinatal postasphyxial brain damage, 52 and delayed cerebral vasospasm after subarachnoid hemorrhage. 41 More recently Nishiki, et al., 36 reported that MgSO 4 administered intraperitoneally prior to ischemia and 60 minutes thereafter is capable of reducing cortical infarct in neonatal rats subjected to transient global ischemia. Data demonstrating magnesium to be a potent neuroprotective agent in vivo are consistent with the active transportation of magnesium into the brain after systemic administration. A recent report by Sjostrom and Wester 49 confirmed that such a transport occurs. Although many of the underlying mechanisms of the
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Magnesium sulfate in reversible cerebral ischemia 121 cytoprotective effect of calcium channel blockers and excitatory amino acid inhibitors in focal ischemia await elucidation, it is known that tissue salvage occurs predominantly in the neocortical infarct border zone, whereas the densely ischemic focus remains relatively unprotected. 48 The cerebroprotective action of 30 mg/kg MgSO 4 , although modest in our 2-hour occlusion group, was evident, as expected, in the periphery of the infarct. Magnesium-treated rats that were subjected to 1.5 hours of ischemia demonstrated more widespread protection involving rostral and caudal cortex and basal ganglia. This was especially prominent in the 90-mg/kg MgSO 4 animals.
Neuroprotective mechanisms of MgSO 4 probably include blockade of calcium channels, inhibition of excitatory neurotransmitter release, and/or blockade of the NMDA-glutamate receptor. Rothman 42 showed that by inhibiting excitatory neurotransmitters with high concentrations of magnesium or specific glutamate antagonists, anoxic neuronal death could be prevented in neuronal cell culture. The importance of inhibition of excitatory synaptic transmission for preventing hypoxic neuronal injury was further confirmed in hippocampal slice preparations. In this model, high concentrations of magnesium reduced the vulnerability of neurons by blocking the persistent phase of anoxia-induced depolarization and by enhancing postischemic recovery of high-energy phosphates. 23, 45 Another mechanism by which magnesium may decrease the size of brain infarct is cerebral vasodilation. Altura and Altura 2 infused MgSO 4 into the carotid arteries of adult rats and showed a dose-dependent vasodilation of intracranial arterioles and venules. The drug also reversed delayed vasospasm after experimental subarachnoid hemorrhage in rats 41 and increased cerebral blood flow after parenteral administration in rat ischemia models. In conscious rats, MgSO 4 antagonizes carotid artery vasoconstriction that is caused by endothelin-I, angiotensin II, and neuropeptide Y. 24 In isolated human cerebral arteries, it inhibits both serotonin-and prostaglandin-elicited constriction and relaxes prostaglandin-preconstricted arteries.
1 Extracellular magnesium affects smooth-muscle contraction by its action on membrane permeability to calcium ions and blocks both L-and N-type voltage-operated calcium channels. 2, 20 Recently Huang and colleagues 19 produced evidence indicating that magnesium may also modulate hypoxic-ischemic events by blocking local excitatory amino acid-induced spasm and rupture of pial microvasculature; a transcranial Doppler ultrasound study in preeclampsia patients by Belfort and Moise 6 also showed that intravenously administered MgSO 4 dilates small intracranial arterial vessels distal to the MCA.
Back and colleagues 4 have shown that the volume of the ischemic penumbra is greater than the volume of the densely ischemic core soon after the onset of focal ischemia. However, during the first hours of ischemia the penumbra is subjected to progressive metabolic compromise by repetitive waves of anoxic depolarization, probably due to glutamate efflux from the deteriorating ischemic core. 16, 18 As a result, infarct progresses over time by incorporating tissue surrounding the ischemic core and, by 3 to 4 hours, the core and the penumbra merge. 13, 22 Magnesium may exert its beneficial effect by selectively antagonizing anoxic neuronal depolarization by blocking NMDA receptors in the penumbra. It has also been suggested that, because magnesium is intimately involved in adenosine triphosphate (ATP) regeneration after ischemia, its cerebroprotective action may be attributed to attenuation of the ATP depletion during the periods of relative hypoxia that occur with each depolarization. 45 Studies of transient focal ischemia in rats have shown that the window of opportunity for tissue salvage by reperfusion is between 1 and 2 hours. 22, 32, 46 We saw no difference in infarct size in our control animals with 1.5 and 2.0 hours of occlusion. This indicates that in our model the time window for salvage of tissue by reperfusion is less than 90 minutes in untreated animals, which is similar to the data published by Memezawa and coworkers 32 in 1992. The effect of the duration of ischemia on infarct size in MgSO 4 -treated animals is difficult to determine from our data. It is possible that the magnesium dose alone determined the infarct size in our study because the relationship between the duration of reversible ischemia and the infarct volume did not reach statistical significance. There was, however, a trend toward smaller infarct volumes with shorter periods of MCA occlusion in MgSO 4 -treated animals and we think this would have been significant had the power of our analysis been greater.
It is known that hypermagnesemia may cause a reduction in plasma insulin levels, resulting in hyperglycemia. 56 Hyperglycemia is known to aggravate the cerebral injury that follows global ischemia 35 and transient focal ischemia, 12, 17, 35 and it might limit the effectiveness of magnesium treatment for cerebral ischemia. 21 The level of hyperglycemia was modest in our study and not significantly increased after treatment. Although the increase in plasma glucose levels observed in our study was small, it may have decreased the efficacy of MgSO 4 , and the use of insulin to control glucose levels might have potentiated the beneficial effects of the magnesium administration. However, because of difficulties inherent in adjusting the insulin dose appropriately and because of evidence that insulin itself may be cerebroprotective in rat transient focal ischemia, 17 we have not used insulin to achieve tighter glucose control in our laboratory. Other magnesium salts, such as MgCl 2 , appear to produce a greater hyperglycemic response 7, 21 than MgSO 4 . Studies using MgSO 4 in concentrations much higher than were used in our study did not report problems with significant hyperglycemia. 9, 36, 52, 57 The anion associated with Mg ++ seems to be responsible for the differential effects on glucose metabolism, as demonstrated in a comparative study by Nishio, et al.
37
Conclusions
Preischemic, intracarotid infusion of MgSO 4 in rats subjected to transient focal cerebral ischemia had a beneficial effect when compared with vehicle-treated control animals. The neuroprotection was dose dependent and could be documented by improved neurological outcome, decreased volume of infarct, and diminished histological evidence of neuronal injury in the ischemic border zone. The cytoprotective effects of intraarterial MgSO 4 were similar in magnitude to those demonstrated in studies of competitive and noncompetitive excitatory amino-acid antagonist drugs. These results suggest that MgSO 4 , a compound with a long history of clinical use, may prove to be a valuable neuroprotective agent if given intraarterially before inducing transient cerebral ischemia during microsurgical or endovascular procedures on the cerebral vessels.
